Suppr超能文献

HIV 感染患者吸入或鼻用皮质类固醇导致的下丘脑-垂体-肾上腺轴抑制。

Hypothalamic-pituitary-adrenal axis suppression by inhaled or nasal corticosteroids in HIV-infected patients.

机构信息

Department of Internal Medicine, Radboudumc Nijmegen, Nijmegen, The Netherlands.

Nij Smellinge Ziekenhuis, Drachten, The Netherlands.

出版信息

Int J Clin Pharm. 2020 Apr;42(2):347-350. doi: 10.1007/s11096-020-00995-5. Epub 2020 Mar 5.

Abstract

Background Inhaled or nasal corticosteroids can cause suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Early detection is important because this suppression can be associated with significant morbidity. Objective To explore the adverse effect of hypothalamic-pituitary-adrenal suppression by local corticosteroids in HIV-infected patients. Method Ambulatory HIV-infected patients were selected if they used both antiretroviral treatment and inhaled or nasal corticosteroid. Suppression of hypothalamic-pituitary-adrenal axis was defined as a morning plasma cortisol below 80 nmol/L or a cortisol below 550 nmol/L during a 250 mcg adrenocorticotropic hormone-stimulation test. Results Twelve patients were tested; four of them were taking a CYP3A4 inhibitor. All patients had a normal morning plasma cortisol. Suppression of the hypothalamic-pituitary-adrenal axis during the ACTH stimulation test was identified in three of the twelve patients. None of these three individuals were taking a CYP3A4 inhibitor. Conclusion Hypothalamic-pituitary-adrenal axis suppression is frequently identified in patients on inhaled or nasal corticosteroids. CYP3A4 inhibitors such as ritonavir or cobicistat may increase the chance of this adverse effect. In this study we did not identify HPA axis suppression in patients taking CYP3A4 inhibitors. This may be related to the fact that 2 of these 4 patients used beclomethasone, a corticosteroid not metabolized by CYP3A4.ClinicalTrials.gov Identifier NCT02501486.

摘要

背景

吸入或鼻用皮质类固醇可导致下丘脑-垂体-肾上腺(HPA)轴抑制。早期发现这一抑制作用很重要,因为它可能与严重的发病率相关。目的:探讨 HIV 感染患者局部皮质类固醇对 HPA 轴抑制的不良影响。方法:选择同时使用抗逆转录病毒治疗和吸入或鼻用皮质类固醇的门诊 HIV 感染患者。HPA 轴抑制定义为清晨血浆皮质醇低于 80nmol/L 或促肾上腺皮质激素刺激试验中皮质醇低于 550nmol/L。结果:共 12 例患者接受了检测,其中 4 例患者正在服用 CYP3A4 抑制剂。所有患者的清晨血浆皮质醇均正常。12 例患者中有 3 例在 ACTH 刺激试验中出现 HPA 轴抑制。这 3 例患者均未服用 CYP3A4 抑制剂。结论:在使用吸入或鼻用皮质类固醇的患者中,HPA 轴抑制很常见。如ritonavir 或 cobicistat 等 CYP3A4 抑制剂可能会增加这种不良反应的发生几率。在本研究中,我们未发现服用 CYP3A4 抑制剂的患者存在 HPA 轴抑制,这可能与这 4 例患者中的 2 例使用了不经过 CYP3A4 代谢的倍氯米松有关。临床试验注册:NCT02501486。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验